Physician profile
Sameera Rasheed
NPI 1659752020
$745.41
in general payments reported to CMS, 2019-2025
12 companies · $79.69 in 2025
The $79.69 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.00 · 2024: $567 · 2025: $79.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.07 | 2024-2025 | |
| Alkermes, INC. | $180.61 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $56.57 | 2024-2025 | Qelbree |
| Indivior INC. | $55.86 | 2024 | Perseris |
| Almatica Pharma LLC | $48.15 | 2024 | Loreev Xr |
| Lundbeck LLC | $43.62 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $42.84 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $20.91 | 2023 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $20.79 | 2024 | Spravato |
| Ironshore Pharmaceuticals INC. | $17.38 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $16.34 | 2024 | Secuado |
| Teva Pharmaceuticals USA, INC. | $13.27 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameera Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.